These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16675200)

  • 21. Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient.
    Arnold DS; Rosse RB; Dickinson D; Benham R; Deutsch SI; Nelson MW
    J Clin Psychiatry; 2004 Dec; 65(12):1723-4. PubMed ID: 15641883
    [No Abstract]   [Full Text] [Related]  

  • 22. Neurocognitive deterioration in elderly chronic schizophrenia patients with and without PTSD.
    Goodman C; Finkel B; Naser M; Andreyev P; Segev Y; Kurs R; Melamed Y; Bleich A
    J Nerv Ment Dis; 2007 May; 195(5):415-20. PubMed ID: 17502807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of the anticholinesterase drug neuromidin in patients with schizophrenia with marked neurocognitive deficits].
    Morozova MA; Beniashvili AG; Rupchev GE; Lepilkina TA; Starostin DS; Brusov OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(11):28-35. PubMed ID: 19008797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia.
    Sacco KA; Creeden C; Reutenauer EL; George TP
    Schizophr Res; 2008 Aug; 103(1-3):326-7. PubMed ID: 18571377
    [No Abstract]   [Full Text] [Related]  

  • 25. Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity?
    Malhotra AK; Burdick KE; Razi K; Bates JA; Sanders M; Kane JM
    Schizophr Res; 2006 Oct; 87(1-3):181-4. PubMed ID: 16820282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of galantamine on cognition and mood during electroconvulsive therapy: a pilot study.
    Matthews JD; Blais M; Park L; Welch C; Baity M; Murakami J; Sklarsky K; Homberger C; Fava M
    J Psychiatr Res; 2008 Jun; 42(7):526-31. PubMed ID: 17681545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Galantamine may improve attention and speech in schizophrenia.
    Ochoa EL; Clark E
    Hum Psychopharmacol; 2006 Mar; 21(2):127-8. PubMed ID: 16482609
    [No Abstract]   [Full Text] [Related]  

  • 28. Wernicke-Korsakoff syndrome and galantamine.
    Phillips BK; Ingram MV; Grammer GG
    Psychosomatics; 2004; 45(4):366-8. PubMed ID: 15232056
    [No Abstract]   [Full Text] [Related]  

  • 29. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Galantamine treatment of cognitive impairment in bipolar disorder: four cases.
    Schrauwen E; Ghaemi SN
    Bipolar Disord; 2006 Apr; 8(2):196-9. PubMed ID: 16542191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
    Deutsch SI; Rosse RB; Schwartz BL; Schooler NR; Gaskins BL; Long KD; Mastropaolo J
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):147-51. PubMed ID: 17656074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Galantamine as an adjunctive treatment in major depression.
    Elgamal S; MacQueen G
    J Clin Psychopharmacol; 2008 Jun; 28(3):357-9. PubMed ID: 18480702
    [No Abstract]   [Full Text] [Related]  

  • 33. Cognitive deficits in adolescents with schizophrenia undergoing antipsychotic treatment.
    Chabrol H; Peresson G; Bonnet D
    Am J Psychiatry; 1999 Mar; 156(3):497-8. PubMed ID: 10080578
    [No Abstract]   [Full Text] [Related]  

  • 34. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.
    Bogaisky M
    Am J Geriatr Psychiatry; 2014 Sep; 22(9):951. PubMed ID: 25109421
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study.
    Cohen AS; Mitchell KR; Strauss GP; Blanchard JJ; Buchanan RW; Kelly DL; Gold J; McMahon RP; Adams HA; Carpenter WT
    Schizophr Res; 2017 Oct; 188():141-143. PubMed ID: 28130004
    [No Abstract]   [Full Text] [Related]  

  • 36. The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome.
    Keefe RS; Poe M; Walker TM; Harvey PD
    J Clin Exp Neuropsychol; 2006 Feb; 28(2):260-9. PubMed ID: 16484097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.
    Freund-Levi Y; Jedenius E; Tysen-Bäckström AC; Lärksäter M; Wahlund LO; Eriksdotter M
    Am J Geriatr Psychiatry; 2014 Apr; 22(4):341-8. PubMed ID: 24035407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory authorities review use of galantamine in mild cognitive impairment.
    Mayor S
    BMJ; 2005 Feb; 330(7486):276. PubMed ID: 15695272
    [No Abstract]   [Full Text] [Related]  

  • 39. An unsubstantiated conclusion.
    Reifler BV; Blazer D
    Am J Geriatr Psychiatry; 2015 Feb; 23(2):220. PubMed ID: 25575935
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
    Miller DD; McEvoy JP; Davis SM; Caroff SN; Saltz BL; Chakos MH; Swartz MS; Keefe RS; Rosenheck RA; Stroup TS; Lieberman JA
    Schizophr Res; 2005 Dec; 80(1):33-43. PubMed ID: 16171976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.